XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Equity and Share Based Compensation (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Fair Value of Stock Option Valuation Assumptions

The following key assumptions were used in the valuation model to value stock option grants for each respective period:

 

 

2023

 

2022

 

2021

Expected volatility

 

85.7% - 87.8%

 

84.0% - 89.9%

 

68.3% - 75.7%

Dividend

 

$nil

 

$nil

 

$nil

Risk-free interest rate

 

2.76% - 4.15%

 

1.41% - 3.28%

 

1.07% - 1.54%

Expected life

 

6.5 years

 

6.5 years

 

4.5 years - 6.9 years

Fair value

 

$0.44 - $0.82

 

$0.93 - $4.33

 

$4.29 - $7.31

Summary of Stock Based Compensation Stock Option

Stock option transactions under the Company’s plan for the years ended December 31, 2023, 2022 and 2021 are summarized as follows:

 

 

Number of
Options

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Term (years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding at January 1, 2021

 

 

3,067,322

 

 

$

5.42

 

 

 

6.82

 

 

$

15,735

 

Granted during 2021

 

 

792,236

 

 

$

8.47

 

 

 

9.78

 

 

$

57

 

Exercised during 2021

 

 

(177,000

)

 

$

1.07

 

 

 

1.14

 

 

$

1,813

 

Forfeited/expired during 2021

 

 

(60,000

)

 

$

10.70

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

3,622,558

 

 

$

6.20

 

 

 

7.89

 

 

$

6,530

 

Exercisable at December 31, 2021

 

 

2,042,663

 

 

$

4.80

 

 

 

5.14

 

 

$

6,001

 

Granted during 2022

 

 

725,360

 

 

$

2.74

 

 

 

9.70

 

 

$

16

 

Exercised during 2022

 

 

(180,000

)

 

$

1.30

 

 

 

0.51

 

 

$

772

 

Forfeited during 2022

 

 

(78,500

)

 

$

8.45

 

 

 

 

 

 

 

Outstanding at December 31, 2022

 

 

4,089,418

 

 

$

5.76

 

 

 

6.77

 

 

$

152

 

Exercisable at December 31, 2022

 

 

2,549,401

 

 

$

5.88

 

 

 

5.46

 

 

$

133

 

Granted during 2023

 

 

3,492,991

 

 

$

0.94

 

 

 

9.34

 

 

$

130

 

Exercised during 2023

 

 

(100,000

)

 

$

0.83

 

 

 

 

 

$

71

 

Forfeited during 2023

 

 

(535,833

)

 

$

4.04

 

 

 

 

 

 

 

Outstanding at December 31, 2023

 

 

6,946,576

 

 

$

3.50

 

 

 

7.54

 

 

$

83

 

Exercisable at December 31, 2023

 

 

3,081,262

 

 

$

6.07

 

 

 

5.44

 

 

$

1

 

Schedule of Nonvested Stock Options Activity

A summary of the status of the Company’s non-vested stock options, and the changes during the year ended December 31, 2023 is presented below:

 

 

Number of
Options

 

 

Weighted
Average Grant
Date Fair
Value

 

 

Aggregate
Intrinsic Value

 

Non-vested at January 1, 2023

 

 

1,540,017

 

 

$

3.72

 

 

 

 

Granted

 

 

3,492,991

 

 

$

0.71

 

 

 

 

Vested

 

 

(739,361

)

 

$

3.89

 

 

 

 

Forfeited

 

 

(428,333

)

 

$

2.76

 

 

 

 

Non-vested at December 31, 2023

 

 

3,865,314

 

 

$

1.07

 

 

$

82

 

Summary of Performance Base Restricted Share Unit

Performance-based restricted share unit activity for the years ended December 31, 2023, 2022 and 2021 is as follows:

 

 

Number of
Performance-based
Restricted Share Units

 

 

Weighted Average
Grant Date Fair Value

 

Outstanding at January 1, 2021

 

 

869,000

 

 

$

5.89

 

Granted

 

 

158,000

 

 

$

7.72

 

Issued

 

 

(487,000

)

 

$

5.70

 

Forfeited/expired

 

 

(310,000

)

 

$

6.66

 

Outstanding at December 31, 2021

 

 

230,000

 

 

$

6.83

 

Exercisable at December 31, 2021

 

 

200,000

 

 

$

6.49

 

Granted

 

 

 

 

 

 

Exercised

 

 

(200,000

)

 

$

6.41

 

Forfeited

 

 

 

 

 

 

Outstanding at December 31, 2022

 

 

30,000

 

 

$

8.31

 

Exercisable at December 31, 2022

 

 

30,000

 

 

$

8.31

 

Granted

 

 

 

 

 

 

Issued

 

 

(10,000

)

 

$

8.31

 

Forfeited/expired

 

 

(20,000

)

 

$

8.31

 

Outstanding at December 31, 2023

 

 

 

 

$

-

 

Exercisable at December 31, 2023

 

 

 

 

$

-